Welcome to
OzStar Therapeutics

In Pursuit of the best Treatment for Type 2 Diabetes.

Aglucator™ is a first-in-class patented Medical Prebiotic developed to improve the effectiveness of the sulphonylurea class of anti-diabetes drugs which include glibenclamide, gliclazide, glipizide, and glimepiride. Combination use of Aglucator™ and sulphonylureas can slow glucose progression and this may reduce or delay the need for more expensive anti-diabetes drugs including insulin injections!

Our Company

A goal-oriented and accomplished company

OzStar Therapeutics Pty Ltd was founded in April 2010 to develop a novel first-in-class treatment for type 2 diabetes. The company received two Commercialisation Australia Government grants to conduct commercial and regulatory due diligence on its technology and to conduct a phase 2 clinical trial, both of which have been successfully completed.

Our mission is to provide a natural treatment that reduces the need for multiple drug therapies including insulin injections for people with type 2 diabetes.

Our vision is to make Aglucator™ the number one Medical Prebiotic for the treatment of type 2 diabetes.

Dr. Nick N Gorgani, BE, MBBS, MS Drug Dev, Phd

Founder, President and CEO of OzStar Therapeutics Pty Ltd

Our Values

We Believe in Perseverance and Unmatched Science


Through the conduct of world-class research for over a decade our team has discovered a novel approach that may assist in helping to ameliorate the diabetes pandemic!

Over a decade of relentless R&D efforts, we have specifically developed Aglucator™ to rejuvenate the sulphonylurea class of anti-diabetes drugs.


Built from seasoned, highly experienced, and dedicated directors, executive team, and scientific/medical advisory board members, OzStar Therapeutics aspires to be one of the world’s best pharmaceutical companies.


OzStar Therapeutics is proud to own a novel technology that has the potential to serve people with type 2 diabetes for decades to come.   In contrast to currently available treatments that lose effectiveness over time, our adjunctive Aglucator™ treatment specifically targets the gut microbiome to help provide significant and sustained blood glucose and HbA1c control.


Directors, executive team, and advisory members of OzStar Therapeutics are eminent individuals who have contributed enormously to the field of their expertise with integrity and respect. 


This new treatment approach has the potential to delay the need for expensive drug use including insulin injections. This may in turn reduce the need for frequent HbA1c monitoring and for new technologies such as continuous blood glucose monitoring.


OzStar will relentlessly continue until our novel treatment is being tried and adapted by hundreds of millions of people with type 2 diabetes worldwide.

Our Products

Committed to Quality, Safety and Sustained Effectiveness

Clinical Development

OzStar Therapeutics conducted several long-term clinical case studies and an Australian Government-backed clinical trial that shows a promising treatment regimen for type 2 diabetes.

Regulatory & Access

Through rigorous due diligence, OzStar Therapeutics fulfilled all requirements to launch its first-in-class product Aglucator™ in Australia as food for special medical purposes.

Intellectual Properties and Trademarks

Within the past decade, OzStar Therapeutics received two families of patents granted in 14 countries with some of these having the highest numbers of people with type 2 diabetes. OzStar Therapeutics obtained a trademark for Aglucator™.

Scientific Exchange

At OzStar Therapeutics we are committed to contributing to the scientific community we engage with. Our clinical trial results were presented at the European Association for the Study of Diabetes (EASD). Subsequently, these results were peer-reviewed and published in an international journal. OzStar CEO has since been invited as a keynote speaker at a number of related international conferences.

Our Purpose

To serve type 2 diabetes patients who deserve better treatments.

Type 2 diabetes is a chronic progressive disease and this results in reduced effectiveness over time of several currently available treatments.   

You may ask:

  • What is the main driving force (aetiology) behind the development and progression of type 2 diabetes?
  • Why do currently marketed drugs commonly lose effectiveness?

We have plenty of emerging scientific information to share with you. Click Health Care Professionals

Our Brands